Collegium Pharmaceutical Announces FDA Grant Of Pediatric Exclusivity For Nucynta Franchise; Extends U.S. Exclusivity To January 2027 For Nucynta And December 2025 For Nucynta ER
Portfolio Pulse from Benzinga Newsdesk
Collegium Pharmaceutical has announced that the FDA has granted pediatric exclusivity for its Nucynta franchise. This extends U.S. exclusivity for Nucynta to January 2027 and for Nucynta ER to December 2025.
June 13, 2024 | 12:05 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Collegium Pharmaceutical has received FDA pediatric exclusivity for its Nucynta franchise, extending U.S. exclusivity for Nucynta to January 2027 and for Nucynta ER to December 2025.
The extension of exclusivity for Nucynta and Nucynta ER is a significant positive development for Collegium Pharmaceutical. It ensures market protection from generic competition for a longer period, potentially leading to sustained revenue from these products.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100